fidrisertib   Click here for help

GtoPdb Ligand ID: 11875

Synonyms: ALK2-IN-1 | BLU-782 | BLU782 | IPN-60130 | IPN60130
Compound class: Synthetic organic
Comment: The chemical structure for fidrisertib was obtained from the WHO proposed INN list 126 (Jan 2022). This matches to the company code BLU-782 via PubChem. The compound is the subject of Blueprint Medicines' patent WO2021030386A1 [2], in which it is described as an activin receptor-like kinase (ALK) inhibitor, with preferred selectivity for ALK2 (ACVR1) and mutant forms of ALK2.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 0
Rotatable bonds 9
Topological polar surface area 84.67
Molecular weight 562.33
XLogP 3.88
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES CCOC1(CCN(CC1)C(C)C)c1ccc(nc1)c1cn2c(c1)c(ccn2)N1CCN(CC1)C(=O)O[C@H]1COCC1
Isomeric SMILES C(C)OC1(CCN(CC1)C(C)C)c1ccc(nc1)c1cc2n(nccc2N2CCN(CC2)C(=O)O[C@H]2COCC2)c1
InChI InChI=1S/C31H42N6O4/c1-4-40-31(9-12-34(13-10-31)23(2)3)25-5-6-27(32-20-25)24-19-29-28(7-11-33-37(29)21-24)35-14-16-36(17-15-35)30(38)41-26-8-18-39-22-26/h5-7,11,19-21,23,26H,4,8-10,12-18,22H2,1-3H3/t26-/m1/s1
No information available.
Summary of Clinical Use Click here for help
BLU-782 was advanced to early stage clinical evaluation in healthy vounteers, to investigate safety, tolerability, pharmacokinetics, and the effect of food on drug administration. Ipsen are progressing this agent (as IPN60130) for fibrodysplasia ossificans progressiva (FOP).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03858075 Safety, Tolerability, Pharmacokinetics, and Food Effect of BLU-782 in Healthy Adults Phase 1 Interventional Blueprint Medicines Corporation
NCT05039515 Study to Assess the Efficacy and Safety of 2 Dosage Regimens of Oral IPN60130 for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP). Phase 2 Interventional Ipsen